US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
SNDK
$1,719.99
▲+0.00%
NVDA
$233.95
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
ASML
$1,867.31
▲+0.00%
MSTR
$160.01
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
SNDK
$1,719.99
▲+0.00%
NVDA
$233.95
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
ASML
$1,867.31
▲+0.00%
MSTR
$160.01
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Applied Biologics
Applied Biologics Publishes New Translational Research Demonstrating Ligament Regeneration with XWRAP®-Based Biologic Augmentation
September 30, 2026
From
Applied Biologics
Via
GlobeNewswire
Applied Biologics Announces Publication of New XWRAP® Translational Research Demonstrating More Favorable Wound-Healing Biology
September 24, 2026
From
Applied Biologics
Via
GlobeNewswire
Applied Biologics Announces Last Patient, Last Visit in CAMPX Randomized Controlled Trial of XWRAP®
September 22, 2026
From
Applied Biologics
Via
GlobeNewswire
Applied Biologics Receives Service-Disabled Veteran-Owned Small Business Certification
September 17, 2026
From
Applied Biologics
Via
GlobeNewswire
Applied Biologics Launches APPB-429 Gene Therapy Program for Diabetic Peripheral Neuropathy
September 15, 2026
From
Applied Biologics
Via
GlobeNewswire
Applied Biologics Welcomes New CMS RAPID Pathway and Expanded CMS-FDA Coordination for Innovative Medical Technologies
September 08, 2026
From
Applied Biologics
Via
GlobeNewswire
Applied Biologics Achieves Key Preclinical Milestone in Disease-Modifying Osteoarthritis Gene Therapy Program
September 03, 2026
From
Applied Biologics
Via
GlobeNewswire
Applied Biologics Activates First Clinical Site in Phase 3 BIOxHEAL™ Trial
September 01, 2026
From
Applied Biologics
Via
GlobeNewswire
Applied Biologics Announces Acceptance of Updated CAMPX XWRAP® Clinical Trial Results for Presentation at SAWC Fall 2026
August 25, 2026
From
Applied Biologics
Via
GlobeNewswire
Applied Biologics CEO and Former Marine F/A-18 Pilot Edward Britt Selected as Honorary Commander at Luke Air Force Base
August 24, 2026
From
Applied Biologics
Via
GlobeNewswire
Applied Biologics Welcomes CMS’ Continued Commitment to Clinical Evidence in Advanced Wound Care
August 19, 2026
From
Applied Biologics
Via
GlobeNewswire
Applied Biologics Announces Acceptance of XWRAP® Translational Research for Presentation at SAWC Fall 2026
August 18, 2026
From
Applied Biologics
Via
GlobeNewswire
Applied Biologics Launches National Health System Partnership Initiative
August 12, 2026
From
Applied Biologics
Via
GlobeNewswire
CMS Proposed 2027 Medicare Policy Continues Recognition of the FDA’s Section 351 Biologic Pathway
August 10, 2026
From
Applied Biologics
Via
GlobeNewswire
Applied Biologics Receives Central IRB Approval for Phase 3 BIOxHEAL™ Clinical Trial
August 05, 2026
From
Applied Biologics
Via
GlobeNewswire
Applied Biologics Marks 10 Years of Continuous AATB Accreditation While Initiating Reaccreditation Process
August 04, 2026
From
Applied Biologics
Via
GlobeNewswire
Applied Biologics Announces Successful GMP Manufacturing of Initial Clinical Lots of BIOxHEAL™
July 30, 2026
From
Applied Biologics
Via
GlobeNewswire
Applied Biologics Expands National Commercial Payer Engagement Strategy for XWRAP®
July 28, 2026
From
Applied Biologics
Via
GlobeNewswire
Applied Biologics Announces Extension of Longstanding System-Wide Agreement With Providence Health & Services for XWRAP®
July 27, 2026
From
Applied Biologics
Via
GlobeNewswire
Applied Biologics Initiates Multi-Center Real-World Outcomes Study of XWRAP® Across Chronic Wound Types
July 21, 2026
From
Applied Biologics
Via
GlobeNewswire
Applied Biologics Announces Submission of XWRAP® Translational Research Abstract for Consideration at SAWC Fall 2026
July 20, 2026
From
Applied Biologics
Via
GlobeNewswire
Applied Biologics Announces Successful Manufacture of First Research Construct for Disease-Modifying Osteoarthritis Gene Therapy Program
July 14, 2026
From
Applied Biologics
Via
GlobeNewswire
Applied Biologics Introduces ECM Preservation Technology™ as the Proprietary Manufacturing Platform Behind XWRAP®
July 09, 2026
From
Applied Biologics
Via
GlobeNewswire
Applied Biologics Announces VA Federal Supply Schedule Contract Modification Supporting Long-Term Access to XWRAP®
July 07, 2026
From
Applied Biologics
Via
GlobeNewswire
Applied Biologics Announces Expanded Strategic Focus on Surgical Applications of XWRAP®
July 01, 2026
From
Applied Biologics
Via
GlobeNewswire
Applied Biologics Announces National Commercial Expansion to Support Continued Growth of XWRAP® and Future Biologic Product Pipeline
June 30, 2026
From
Applied Biologics
Via
GlobeNewswire
Applied Biologics Announces Completion of Translational Research Supporting the Biologic Performance of XWRAP®
June 24, 2026
From
Applied Biologics
Via
GlobeNewswire
Applied Biologics Announces Submission of Abstract of Single-Layer Amniotic Membrane Plus Standard of Care for Chronic Diabetic Foot Ulcers: An Updated Analysis of The Campx Trial to SAWC Fall 2026
June 23, 2026
From
Applied Biologics
Via
GlobeNewswire
Applied Biologics Announces Completion of Planned Enrollment Activities in the CAMPX Randomized Controlled Trial Evaluating XWRAP®
June 17, 2026
From
Applied Biologics
Via
GlobeNewswire
Applied Biologics Reports Statistically Significant Improvement in Wound Closure Outcomes in Updated Analyses of the CAMPX Randomized Controlled Trial Evaluating XWRAP®
June 15, 2026
From
Applied Biologics
Via
GlobeNewswire
